

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/917,376	07/28/2001	Shi-You Ding	NREL 01-36

CONFIRMATION NO. 9956

23712
PAUL J WHITE, SENIOR COUNSEL
NATIONAL RENEWABLE ENERGY LABORATORY (NREL)
1617 COLE BOULEVARD
GOLDEN, CO 80401-3393

FORMALITIES LETTER



OC000000006511240

Date Mailed: 09/04/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

RECEIVED
JAN 15 2002
TECH CENTER 1600/2900

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY



1633
Box 552

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Shi-You Ding et al.)
Serial No.: 09/917,376) Art Unit: 1633
Filing Date: July 28, 2001) Examiner: Not Yet Accorded
Title: Thermal Tolerant Avicelase from)
Acidothermus cellulolyticus) Atty. Dkt. No.: NREL 01-36

RECEIVED
JAN 15 2002
ER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I hereby certify that the following attached items:

- (1) Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosure - Part 3 [2 pages]
- (2) Statement for Support Filing and Submission in Accordance
with 37 CFR §§ 1.821-1.825 [2 pages]
- (3) Sequence Listing [14 pages]
- (4) Copy Computer Readable Disk
- (5) Postcard receipt

are being deposited in the United States Postal Service as first class mail, postage pre-paid, in an envelope addressed to: Assistant Commissioner for Patents, Customer Service Center, Initial Patent Examination Division, Washington, DC. 20231 on this 30th day of October 2001.

Brenda E. Brantley
Brenda E. Brantley
Patent Administrator

National Renewable Energy Laboratory
1617 Cole Boulevard
Golden, CO 80401
303/384-7572
303/384-4799 (fax)